Back to today’s briefing

Story perspectives

Doctors Without Borders Urges Gilead to Sell HIV Drug Directly

3/31/2026

22 3 Full Breakdown

Summary

Story summary

Doctors Without Borders/Médecins Sans Frontières (MSF) urges Gilead Sciences to sell lenacapavir directly to MSF for humanitarian settings.
Lenacapavir is an injectable pre-exposure prophylaxis (PrEP) given twice a year, aiding adherence.
MSF says 1.3 million people contract HIV annually and accuses Gilead of blocking access.
Gilead says production is expanding, while the Global Fund to Fight AIDS, Tuberculosis and Malaria has insufficient supply.

1 of 1

Story summary

Doctors Without Borders/Médecins Sans Frontières (MSF) urges Gilead Sciences to sell lenacapavir directly to MSF for humanitarian settings.
Lenacapavir is an injectable pre-exposure prophylaxis (PrEP) given twice a year, aiding adherence.
MSF says 1.3 million people contract HIV annually and accuses Gilead of blocking access.
Gilead says production is expanding, while the Global Fund to Fight AIDS, Tuberculosis and Malaria has insufficient supply.